February 2, 2015 By Alex Keown , BioSpace.com Breaking News Staff BOSTON - WaVe Life Sciences secured $18 million in funding to advance the company's development of stereopure nucleic acid therapeutics, including antisense and exon-skipping drug candidates, which are being developed to treat diseases across multiple therapeutic areas. Nucleic acid therapies are part of the next generation of medications that "promise to broadly and fundamentally improve the treatment of human disease," said Paul Bolno , CEO of WaVe Life Sciences .
http://ift.tt/1z63cwo
http://ift.tt/1z63cwo
No comments:
Post a Comment